ZTS Stock Recent News

Zoetis received a conditional license for its bird flu vaccine from the US Department of Agriculture to help fight the spread of the disease on poultry farms. Here's what CEO Kristin Peck had to say

One day after unveiling quarterly results that disappointed the market and engendered a stock sell-off, Zoetis (ZTS -4.49%) shares again tumbled. As of late-session trading on Friday, they were down by 4%, in no small part due to several analyst price target cuts.

Zoetis said on Friday its bird flu vaccine has received the U.S. Department of Agriculture's conditional license for use in poultry.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #HPAI--Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is labelled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonable expectation of efficacy based on serology data. Zoetis is committed to supporting poultry producers with scientif.

Zoetis CEO Kristin Peck joins 'Closing Bell Overtime' to talk its Avian Flu vaccine, the impact of tariffs, and more.

Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing power in animal health, coupled with high R&D investment and a wide moat, make it a strong long-term play on emerging market growth. Despite regulatory risks and currency headwinds, Zoetis' dependable earnings and high operating margins justify a 12-month price target of $200/share.

ZTS stock falls despite better-than-expected fourth-quarter results due to a weak 2025 outlook.

Zoetis Inc. (NYSE:ZTS ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Steve Frank - IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Russell Yuen - William Blair Balaji Prasad - Barclays Chris Schott - JPMorgan Glen Santangelo - Jefferies Navann Ty - BNP Paribas Chris LoBianco - TD Securities Andrea Alfonso - UBS Daniel Clark - Leerink Partners Operator Welcome to the Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.

Shares of Zoetis (ZTS -6.17%), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up short in its fourth quarter.

Zoetis (ZTS -8.79%), the leader in animal health solutions, released its fourth quarter results for 2024 on Feb. 13. The company reported an adjusted earnings per share (EPS) of $1.40, which exceeded the consensus estimate of $1.36.